INSYS Therapeutics Inc.

INSYS Therapeutics Inc.

To improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs.
1d 5d 1m 6m 1y Max

INSYS Therapeutics Inc. News

12 Jun

Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News

Insys Therapeutics bankruptcy news for Wednesday has INSY stock heading higher.Source: Insys TherapeuticsInsys Therapeutics (NASDAQ:INSY) notes that it now has approval from the U.S. Bankruptcy Court for...

12 Jun

Zynerba Up on Second Patent for Cannabidiol Candidate in 2019

Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.

12 Jun

Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

12 Jun

Insys Therapeutics' stock jumps after bankruptcy court approves 'First Day' motions

Shares of Insys Therapeutics Inc. shot up 83% in premarket trade Wednesday, after the bankrupt opioid maker said it received interim court approvals for its "First Day" motions related to bankruptcy...

12 Jun

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S....

11 Jun

Insys Down on Bankruptcy News Amid Increasing Legal Expenses

Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.

11 Jun

Stoke Therapeutics Files Proposed Terms For IPO

Quick Take Stoke Therapeutics ( STOK ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for severe...

11 Jun

Investors are pinning hopes on this asset again — but beware, says Saxo Bank

Our call of the day, from Saxo Bank’s head of commodity strategy Ole Hansen, cautions investors against getting too excited over this haven asset again too soon.

10 Jun

Chandler opioid maker files for bankruptcy protection

Costs related to recent federal settlements and other lawsuits have forced the Valley drugmaker to file for bankruptcy protection.

10 Jun

Top Trending: Insys files for bankruptcy, Hudson's Bay offers to go private and more

Yahoo Finance's Adam Shapiro fills you in on the top trending news stories that you need to know.

Load more

About INSYS Therapeutics Inc.

The culture of compliance efforts at INSYS is the promotion of ethical behavior by employees and corporate responsibility by the company.

In accordance with our values, the INSYS compliance function supports the development and implementation of practices to facilitate compliance with applicable laws and corporate policy. As importantly, due diligence in preventing and detecting misconduct or non-compliance with laws or regulations is supported by these effective compliance systems.

Our employees are encouraged to report concerns or suspected cases of misconduct without the fear of retaliation. Employees can do this through line managers or through our confidential Compliance Helpline reporting channels. All concerns and allegations are fairly and independently investigated, and disciplinary action, if applicable, is commensurate with the issues presented.

The INSYS Compliance Helpline enables employees to report a concern or receive information or advice anonymously. The Compliance Helpline can be reached by phone or online via the web–reporting tool. Accessible 24 hours a day, 7 days a week, 365 days a year and offered in 70 languages, the Compliance Helpline is operated by specially trained third–party representatives.


Saeed Motahari
President & Chief Executive Officer
Andrew G. Long
Chief Financial Officer
Mark Nance
Chief Legal Officer & General Counsel
Ted A. Smith III
Vice President, Human Resources
Venkat R. Goskonda
Senior Vice President, Research & Development
Danny L. Tuck
Senior Vice President, Quality Operations
Ahmed Elkashef
Vice President of Clinical Development
B. Sanga Emmanuel
Vice President, Chief Compliance Officer
Vikram Malhotra
Vice President, Corporate Development
Scott Warlick
Vice President, Manufacturing
Steven Meyer
Elizabeth Bohlen
Vaseem Mahboob
Trudy Vanhove
Pierre Lapalme
Rohit Vishnoi
$ 0.29
Market cap:
25.354 M